ArticleDermatology practical & conceptual2022
Papulopustular Rosacea Treated With Ivermectin 1% Cream: Remission of the Demodex Mite Infestation Over Time and Evaluation of Clinical Relapses.
Article in Dermatology practical & conceptual, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 19 citations in OpenAlex.
- Efficacy of AOPT Combined With Collagen Dressings on Facial Flushing and Skin Barrier Function in Patients With Rosacea.International wound journal · 2026Trial
- Asymptomatic Bilateral Demodicosis of the Nipple.Cureus · 2026Article
- Inflammatory memory as a potential driver of rosacea pathogenesis: integrating mechanisms of chronic relapse and perspectives on disease modification.Frontiers in immunology · 2026Review
- Dermoscopic Response Predictors in Papulopustular Rosacea Treated with Topical Ivermectin and Metronidazole: A Prospective Observational Comparative Study.Clinical, cosmetic and investigational dermatology · 2026Article
- Sebum-Selective 1,726-nm Laser Therapy for Papulopustular Rosacea Associated withClinical, cosmetic and investigational dermatology · 2026Article
- Efficacy of topical Ivermectin in controlling humanParasite epidemiology and control · 2025Article
- Significance ofMedicina (Kaunas, Lithuania) · 2025Review
- Evaluation of the safety and effectiveness of combination therapy with 1% ivermectin solution in moderate to severe rosacea: a cohort study.Journal of medical microbiology · 2025Article
- Current Trends and Future Insights on Rosacea Treatment: A Bibliometric Analysis.Clinical, cosmetic and investigational dermatology · 2025Article
- Follicular scales, scalp and ocular involvement in patients with papulopustular rosacea: prevalence and association with Demodex mite proliferation.Dermatology reports · 2024Article
- Deciphering Childhood Rosacea: A Comprehensive Review.Journal of clinical medicine · 2024Review
- Evaluating the Efficacy of Oral Ivermectin on Clinical Symptoms andDrug design, development and therapy · 2024Article
- Ozonated Hydrotherapy Combined with LED Yellow Light Irradiation and Oral Minocycline Treatment for Mild to Moderate Papulopustular Rosacea: A Comparative Retrospective Study.Clinical, cosmetic and investigational dermatology · 2024Article
- Therapeutic strategies focusing on immune dysregulation and neuroinflammation in rosacea.Frontiers in immunology · 2024Review
- Has the Use of the Mask Exacerbated Rosacea During the Pandemic?Dermatology practical & conceptual · 2023Article
- Patient Education with New Media Integration Self-Management Support Model Improves Therapeutic Outcomes of Rosacea Patients.Patient preference and adherence · 2023Article
- Effect of COVID-19 and Face Masks on the Condition of Rosacea - A Retrospective Analysis of 87 Patients.Clinical, cosmetic and investigational dermatology · 2023Article
- Comparison of in vitro Killing Effect of Thai Herbal Essential Oils, Tea Tree Oil, and Metronidazole 0.75% versus Ivermectin 1% onClinical, cosmetic and investigational dermatology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Topical ivermectin is an anti-inflammatory and anti-Demodex drug for papulopustular rosacea. Rosacea is a relapsing disease and the time between recurrences should be considered alongside efficacy. Objectives: The aims of this study were to assess the time of first relapse and relapse rates of Demodex mite infestation and papulopustular rosacea. Methods: We conducted a prospective study of subjects affected by different degrees of papulopustular rosacea. Patients that achieved a complete response after treatment were monitored every 4 weeks and up to 32 additional weeks. For each patient, we evaluated recording the time to first relapse and relapse rate of Demodex mite infestation and rosacea. Results: The overall success rate on Demodex infestation was 87.5% only 12.5% relapse. Ivermectin leads to complete response in 70% of patients. Median time to relapse was 140 days, the mean time was 152 days. The global success rate was 54.76%. Conclusions: Topical ivermectin keeps a remission of Demodex infestation and clinical remission for long time. We proposed a twice weekly ivermectin maintenance therapy to reduce recurrences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.